EU Novel Food Regulation CBD: Country Status, EFSA Safety & Guide

What the Novel Food Framework Actually Says

EU novel food regulation CBD is a policy framework that governs how cannabidiol extracts reach consumers, requiring safety assessment before formal market authorisation under the EU 2015/2283 rules. If you have tried to buy a CBD oil, capsule, or gummy anywhere in Europe over the past few years, you have probably bumped into the phrase "novel food." It sounds bureaucratic because it is. But the framework behind it directly shapes which CBD products reach shop shelves, how they are labelled, and whether they can be sold as food supplements in your country. This article unpacks the framework itself, the country-by-country patchwork it has created, and what it all means if you are comparing CBD formats as an adult consumer.

AZARIUS · What the Novel Food Framework Actually Says

The core idea is simple: any food or food ingredient that was not consumed "significantly" within the EU before 15 May 1997 is classified as a novel food. Hemp seeds and hemp-seed oil have a long consumption history and are generally exempt. Extracts of Cannabis sativa L. that are enriched in cannabidiol (CBD), however, were not part of the European diet before that cut-off date — at least not in the concentrated forms sold today. The European Commission's Novel Food Catalogue lists CBD extracts as novel, meaning they require a safety assessment and formal authorisation before they can be marketed as food or food supplements (European Commission, Novel Food Catalogue, updated 2023).

Status by EU Member State

Enforcement of the EU novel food regulation CBD framework varies dramatically from one country to the next. The table below summarises the picture across major EU and EEA markets as of early 2025. A critical caveat: the status changes over time, sometimes quickly. Verify current conditions for your jurisdiction before drawing conclusions.

AZARIUS · Status by EU Member State

Note: This table is a snapshot. The status changes over time under the EU 2015/2283 framework and national implementation approaches. Always verify current conditions for your jurisdiction.

The EFSA Safety Assessment — Where Things Stand

EFSA has not yet granted formal authorisation for any CBD novel-food application. For a novel food to receive EU-wide authorisation, the applicant must submit a safety dossier to the European Food Safety Authority (EFSA). EFSA then conducts a scientific risk assessment. Several CBD companies have submitted applications — the European Commission's novel-food application tracker listed over 50 pending CBD-related applications as of mid-2024.

AZARIUS · The EFSA Safety Assessment — Where Things Stand

In early 2025, EFSA published an updated statement on the safety of cannabidiol as a novel food. The panel established a provisional safe intake level of approximately 2 mg of CBD per kilogram of body weight per day for adults. For a 70 kg adult, that works out to roughly 140 mg per day (EFSA Panel on Nutrition, Novel Foods and Food Allergens, 2025). That figure is based on the available toxicological and clinical data, including liver-enzyme (ALT) elevation observed in high-dose pharmaceutical CBD trials.

The word "provisional" matters. EFSA flagged data gaps — particularly around long-term exposure at consumer-supplement doses and potential interactions with common medications. The panel noted that CBD inhibits cytochrome P450 enzymes (CYP3A4 and CYP2C19), which are involved in metabolising a wide range of drugs. This is the same metabolic pathway flagged by the so-called "grapefruit warning": if a medication label says "do not take with grapefruit," CBD may interact with it too. Talk to your doctor before combining CBD with any prescription medication.

Until EFSA completes full authorisations and the European Commission formally approves specific CBD novel-food applications, the status of CBD food supplements remains transitional — technically unauthorised at EU level, but tolerated to varying degrees by national authorities. The EUDA (formerly EMCDDA) has noted this patchwork enforcement pattern across member states in its monitoring reports (EMCDDA, Cannabis policy: status and recent developments, 2023).

What Novel Food Status Means for the Product on the Shelf

Novel-food classification affects CBD products in three practical ways that determine what you can actually order and what the label should say.

AZARIUS · What Novel Food Status Means for the Product on the Shelf

1. Labelling. Products sold as food supplements must comply with EU rule 1169/2011 on food information to consumers. That means a full ingredients list, nutritional declaration where applicable, and — critically — no health claims that have not been authorised by EFSA under the EU Nutrition and Health Claims framework (EC) No 1924/2006. As of 2025, zero health claims have been authorised for CBD. None. Some brands use phrases like "supports sleep" or "relieves stress" on their packaging — these are examples of non-compliant wording identified by the European Commission (EC Register of Nutrition and Health Claims, 2024), because EFSA has not evaluated or authorised any such claims for CBD. Similarly, any label stating "cures insomnia" would be a medicinal claim requiring pharmaceutical authorisation, according to the same EC guidance. Any product label making such unverified claims is technically non-compliant with EU food-supplement labelling requirements.
2. THC limits. The EU's common agricultural policy sets a maximum THC content of 0.3% in industrial hemp cultivars (raised from 0.2% in 2023 under EU rule 2021/2115). However, finished consumer products are subject to national THC limits, which vary. The Netherlands, for example, applies a stricter threshold of 0.05% THC in finished products. Germany and Austria broadly follow the 0.2% raw-material standard. These limits determine whether a full-spectrum CBD extract — which naturally contains trace THC — can be sold in a given market.
3. Product format. The novel-food classification applies specifically to CBD when it is intended for ingestion — oils, capsules, gummies, drinks, edibles. Topical products (creams, balms) fall under the EU Cosmetics framework (EC) No 1223/2009 instead, which has its own set of requirements. Vape products sit under the Tobacco Products Directive (2014/40/EU) in most member states, though national implementation varies. The pathway you care about depends on how you plan to use the product.

The UK Divergence After Brexit

The United Kingdom now runs its own parallel process through the Food Standards Agency (FSA), separate from the EU framework. In 2020, the FSA announced that CBD food products would need novel-food authorisation, and set a deadline for companies to submit applications. Those that applied and made the FSA's "validated list" were permitted to keep products on sale while their applications were assessed.

In October 2023, the UK's Committee on Toxicity (COT) and the Advisory Committee on Novel Foods and Processes (ACNFP) published a joint statement establishing a provisional acceptable intake of 10 mg of CBD per day for healthy adults — significantly lower than the EFSA figure of ~2 mg/kg/day (COT/ACNFP Statement, October 2023). The COT based this on a more conservative interpretation of the liver-safety data. The FSA has not yet finalised its position, and the validated-list process remains ongoing. For UK-based shoppers, this means the picture is still shifting.

What Novel Food Status Does Not Tell You

The framework governs market access and safety thresholds. It does not tell you which CBD concentration to choose, whether oil or capsules suit your routine better, or how bioavailability differs between sublingual and oral formats. Those are format-education questions covered elsewhere — see the articles on CBD oil percentages explained, CBD bioavailability by format, and CBD oil vs capsules for detailed breakdowns. If you want to get a practical sense of how different CBD products compare, those guides are a better starting point than any policy document.

AZARIUS · What Novel Food Status Does Not Tell You

The framework also does not address the one question most shoppers actually want answered: "does CBD do anything?" That is a research question, not a policy one, and the evidence base is still developing. EFSA's safety assessment is about toxicological risk, not efficacy. The two are separate processes, and conflating them is one of the most common misunderstandings in the CBD space. We are honest about this limitation: no retailer, including us, can tell you CBD will produce a specific effect, because the science is not there yet for most consumer-supplement use cases.

Comparing CBD Formats Under the Novel Food Framework

Different CBD product formats face different compliance requirements under the EU novel food regulation CBD framework, which can affect what you find available to buy in your market. Here is a quick comparison:

AZARIUS · Comparing CBD Formats Under the Novel Food Framework

If you are deciding whether to order a CBD oil, capsule, or gummy, the novel-food classification applies equally to all three. The practical differences — onset time, bioavailability, convenience — are covered in our format comparison articles rather than in policy documents.

Practical Takeaways for Shoppers

• Check the label. A compliant CBD food supplement should list CBD content per serving, a full ingredients list, and a batch or lot number. If it makes unverified wellness claims, that is a red flag under EU food-supplement labelling requirements — those claims are not authorised.
• Know your country's approach. Enforcement varies. A product on sale in the Netherlands may not be available in Sweden or Denmark. If you are ordering across borders within the EU, the conditions of your destination country apply.
• Understand the THC threshold. Full-spectrum CBD products contain trace amounts of THC within permitted limits. Those limits differ by country. If you are subject to workplace drug testing, even trace THC within permitted thresholds may register on a sensitive screening test.
• Topicals and vapes are different categories. If your interest is in a CBD cream or vape pen rather than an oil or gummy, different frameworks apply — cosmetics and tobacco-products directives respectively, not novel-food requirements.
• The situation is not static. EFSA's provisional safe-intake figure, the pending novel-food applications, and the UK's parallel FSA process all mean that the picture in 2026 may look different from today. Bookmark your national food-safety authority's CBD guidance page and check back periodically.
• Buy from transparent brands. When you order CBD products, look for brands like Cibdol that publish third-party lab reports (certificates of analysis) for each batch. This is the simplest way to verify that what is on the label matches what is in the bottle.

This article is consumer education. The status of CBD products varies by EU member state and changes over time under the EU 2015/2283 framework and national approaches. Verify current conditions for your jurisdiction.

AZARIUS · Practical Takeaways for Shoppers

Important: This article is consumer education and is not medical advice. CBD products are food supplements, not medicines. Research on CBD is ongoing and evidence remains limited or mixed for many topics. Talk to your doctor before use if you are pregnant, breastfeeding, taking medication, scheduled for surgery, or living with a health condition. Keep CBD products out of reach of children and pets.

This article has been reviewed for factual and editorial accuracy by Toine Verleijsdonk (Cibdol brand manager) and Joshua Askew (Editorial Director). It has NOT been reviewed by a licensed medical practitioner and does not constitute medical advice.

References

1. EU 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods. Official Journal of the European Union, L 327/1.
2. European Commission Novel Food Catalogue — Cannabis sativa L. entry (updated 2023).
3. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). Statement on the safety of cannabidiol (CBD) as a novel food: updated assessment. EFSA Journal, 2025.
4. Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment (COT) and Advisory Committee on Novel Foods and Processes (ACNFP). Joint statement on cannabidiol (CBD), October 2023.
5. EU rule 1169/2011 on the provision of food information to consumers. Official Journal of the European Union, L 304/18.
6. EC framework 1924/2006 on nutrition and health claims made on foods. Official Journal of the European Union, L 404/9.
7. EU rule 2021/2115 establishing support for strategic plans (CAP reform — hemp THC threshold increase to 0.3%).
8. Conseil d'État (France), Decision No. 449919, January 2022 — partial annulment of the interministerial decree banning CBD flower.
9. Millar SA, Stone NL, Yates AS, O'Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology. 2018;9:1365. DOI: 10.3389/fphar.2018.01365.
10. EMCDDA (European Monitoring Centre for Drugs and Drug Addiction). Cannabis policy: status and recent developments. Lisbon, 2023.
11. European Commission Register of Nutrition and Health Claims Made on Foods, 2024.

Last updated: April 2026